![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-gr1.jpg)
glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor
Description
Think of your gut like a garden
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13668-025-00649-w/MediaObjects/13668_2025_649_Fig1_HTML.png)
Additionally, novel diagnostic tools, such as corneal confocal microscopy and biomarker-based tests, have improved early detection and intervention
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt-250812-glp-1-inhibitors-800x450.jpg)
Experts say theres no evidence GLP-1s can be absorbed through the skin and these patches dont contain the FDA-approved medicine anyway.
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://jcadonline.com/wp-content/uploads/Cotter2_Table1.gif)
Call (954) 551-3508.
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://jddonline.com/wp-content/uploads/2025/04/JDD-BLOG-IMAGE-TEMPLATE-2.png)
NOC= Notice of Compliance.
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b0d/11547001/a1b22dfe9423/jcm-13-06292-g004.jpg)
Starting in mid-2026, Medicare will begin covering these drugs for select patient groups and state Medicaid programs have the option to adopt similar coverage at these discounted rates
![glp-1 for hs Translated article] Glucagon-Like Peptide-1 Agonists Treating Obesity in Patients With Immune-Mediated Skin Diseases Impact of GLP- 1 Receptor](https://swoop.com/wp-content/uploads/2026/01/HS-patients-share-benefits-of-GLP-1s-on-their-HS-symptoms.png)
